Investing.com – U.S. stocks were mixed after the close on Wednesday, as gains in the Basic Materials, Telecoms and Consumer Goods sectors led shares higher while losses in the...
By Sam Boughedda Charles River Laboratories (NYSE:CRL) shares plummeted over 14% Wednesday after the company said in its latest earnings report that it has received a subpoena from...
Last week’s stock market rally had a few anomalies that investors should cast a wary eye on. The main oddity saw investors pull billions of dollars out of two of the biggest...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Charles River Laboratories International, Inc. is a full service, non-clinical contract research company. The Company provides research models required in research and development of new drugs, devices, and therapies. The Company's segments include Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment includes the research models, research model services, and research and GMP-compliant cells businesses. The DSA segment includes services required to take a drug through the early development process, including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions and Biologics Solutions (Biologics).
|Average||256.50 (+33.06% Upside)|
|No. of Analysts||16|